Paul J. Schmitt
With clinical and pre-clinical operating companies in 7 countries, Chrysalis’ clients included over 250 biotech and pharmaceutical industry companies in 26 countries.
In April 1999, Chrysalis was merged with Phoenix International, Inc. (NASDAQ: PHXI). Prior to forming Chrysalis, Mr. Schmitt joined DNX as the company’s first President and Chief Executive Officer in 1988. While as CEO of DNX, Mr. Schmitt formed Nextran, a joint venture with Baxter Health Care focused on genetically engineered organ and blood substitute products.